Evidence map›Paper›PMID 36364740›Full record

Trial reportNutrients2022

Efficacy and Safety of Fig (

Tatsuya Abe, Yukari Koyama, Kosaku Nishimura, Aya Okiura, Toru Takahashi

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. In Vitro and In Vivo Anti-Psoriasis Activity ofLife (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Tatsuya AbeToyo Institute of Food Technology, 23-2, 4-Chome, Minami-Hanayashiki, Kawanishi 666-0026, Hyogo, Japan.ORCID 0000-0002-3878-2306
Yukari KoyamaToyo Institute of Food Technology, 23-2, 4-Chome, Minami-Hanayashiki, Kawanishi 666-0026, Hyogo, Japan.
Kosaku NishimuraToyo Institute of Food Technology, 23-2, 4-Chome, Minami-Hanayashiki, Kawanishi 666-0026, Hyogo, Japan.
Aya OkiuraToyo Institute of Food Technology, 23-2, 4-Chome, Minami-Hanayashiki, Kawanishi 666-0026, Hyogo, Japan.
Toru TakahashiToyo Institute of Food Technology, 23-2, 4-Chome, Minami-Hanayashiki, Kawanishi 666-0026, Hyogo, Japan.
Toyo Institute of Food Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atopic dermatitis (AD) is a chronic, recurrent pruritic skin disease with repeated remissions and exacerbations. Various factors, such as allergies, skin conditions and lifestyle, combine to cause AD, making it difficult to cure completely. Although AD symptoms are suppressed with medications, this is a long-term effort and burden on patients. Thus, safer drugs and alternatives are needed. We previously found that consumption of tea prepared from fig (

Indexed as

Dermatitis, AtopicFicusHypersensitivityDouble-Blind MethodHumansSeverity of Illness IndexTeaTreatment OutcomeTeaatopic dermatitisEczema Area and Severity Index (EASI)Ficus caricafunctional foodRCT

Identifiers

PMID36364740
PMCPMC9658579
OpenAlexW4307350574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.